Abstract
Bowman-Birk inhibitor concentrate (BBIC) is asoybean extract enriched in the BowmanBirk inhibitor, aprotein protease inhibitor. The Bowman-Birk inhibitorcan inhibit proteases released from inflammation mediating cells and suppress superoxide anionradical secretion from immunocytes. This studyinvestigates the ability of Bowman-Birk inhibitorconcentrate to inhibit colon inflammation in the dextransulfate sodium model of ulcerative colitis, aninflammatory bowel disease. When compared to mice on astandard diet, mice given food supplemented with 0.5%BBIC during and after dextran sulfate sodium treatment showed suppression of three of four scoredhistopathological inflammation criteria (P < 0.01),total histopathological score (P < 0.01), a 15% lowermortality rate (P < 0.01), and a delayed onset of mortality. We conclude that dietaryBowman-Birk inhibitor concentrate can beneficiallyaffect dextran sulfate sodium-treated mice and may beuseful in the treatment of human inflammatory boweldiseases, particularly ulcerative colitis.
Similar content being viewed by others
REFERENCES
Yavelow J, Collins M, Birk Y, Troll W, Kennedy AR: Nanomolar concentrations of Bowman-Birk soybean protease inhibitors suppress X-ray induced transformation in vitro. Proc Natl Acad Sci USA 82:5395–5399, 1985
Kennedy AR: Anticarcinogenic activity of protease inhibitors: Overview. In Protease Inhibitors as Cancer Chemopreventive Agents. W Troll, AR Kennedy (eds). New York, Plenum Press, 1993, pp 9–64
Kennedy AR, Szuhaj BF, Newberne PM, Billings PC: Preparation and production of a cancer chemopreventive agent, Bowman-Birk inhibitor concentrate. Nutr Cancer 19:281–302, 1993
Larionova NI, Gladysheva IP, Tikhonova TV, Kazanskaia NF: Inhibition of cathepsin G and elastase from human granulocytes by multiple forms of the Bowman-Birk type of soy inhibitor. Biochemistry (Moscow) 58:1437–1444, 1993
Tikhonova TV, Gladysheva IP, Kazanshaya NF, Larionova NI: Hydrolysis of elastin by human leukocyte elastase and cathepsin G: Inhibition by Bowman Birk type inhibitor. Biochemistry (Moscow) 59:1295–1299, 1994
Gladysheva IP, Larionova NI, Gladysheva DP, Tikhonova TV, Kazanskaia NF: The classical Bowman-Birk soy inhibitor is an effective inhibitor of human granulocyte alpha-chymotrypsin and cathepsin G. Biochemistry (Moscow) 59(4):513–518, 1994
Ware JH, Wan XS, Rubin H, Schechter NM, Kennedy AR: Soybean Bowman-Birk protease inhibitor is a highly effective inhibitor of human mast cell chymase. Arch Biochem Biophys 344:133–138, 1997
Frenkel K, Chrazan K, Ryan CA, Wiesner R, Troll W: Chymotrypsin-specific protease inhibitors decrease H2O2 formation by activated human polymorphonuclear leukocytes. Carcinogenesis 8:1207–1212, 1987
Podolsky DK: Inflammatory bowel disease. N Engl J Med 325:928-937, 1008–1016, 1991
Glickman RM: Inflammatory Bowel disease: Ulcerative colitis and Crohn's disease. In Harrison's Principles of Internal Medicine. KJ Isselbacher, et al (eds). New York, McGraw-Hill, 1994, pp 1403-1417
Bohe M: Pancreatic and granulocytic endoproteases in faecal extracts from patients with active ulcerative colitis. Scand J Gastroenterol 22:59–64, 1987
Bohe M, Genell S, Ohlsson K: Protease inhibitors in plasma and faecal extracts from patients with active inflammatory bowel disease. Scand J Gastroenterol 21:598–604, 1986
Hawkins JV, Emmel EL, Feuer JJ, Nedelman MA, Harvey CJ, Klein HJ, Rozmiarek J, Kennedy AR, Lichtenstein GR, Billings PC: Protease activity in a hapten-induced model of ulcerative colitis in rats. Dig Dis Sci 42:1969–1980, 1996
Hanauer SB, Baert F: Medical therapy of inflammatory bowel disease. Med Clin North Am 78:1413–1426, 1994
Das KM: Some current perspectives on the etiology and pathogenesis of ulcerative colitis. In Ulcerative Colitis.CA O'Morain (ed). Boca Raton, Florida, CRC Press, 1991, pp 47–54
Wargovich MJ, Bauer AR, Hu PJ, Sumiyoshi H: Dietary factors and colorectal cancer. Gastroenterol Clin North Am 7:727–745, 1988
Rudolph U, Finegold MJ, Rich SS, Harriman GR, Srinivasan Y, Brabet P, Boulay G, Bradley A, Birnbaumer L: Ulcerative colitis and adenocarcinoma of the colon in G-alpha-i2-deficient mice. Nature Genet 10:143–150, 1995
Dayal Y, DeLellis RA: The gastrointestinal tract. In Robbins Pathologic Basis of Disease. RS Cotran, V Kumar, SL Robbins (eds). Philadelphia, WB Saunders, 1989, pp 827–910
Pena AS, Shivanada S, Mayberry JF: Epidemiology of ulcerative colitis. In Ulcerative Colitis. CA O'Morain (ed). Boca Raton, Florida, CRC Press, 1991, pp 1–8
Senda S, Fujiyama Y, Bamba T, Hosoda S: Treatment of ulcerative colitis with camostat mesilate, a serine protease inhibitor. Intern Med 32:350–354, 1993
Birk Y: Proteinase inhibitors from plant sources. Methods Enzymol 45:695–751, 1975
Birk Y: The Bowman-Birk inhibitor. Int J Peptide Protein Res 25:113–131, 1985
Billings PC, Clair WHS, Maki PA, Kennedy AR: Distribution of the Bowman-Birk inhibitor in mice following oral administration. Cancer Lett 62:191–197, 1992
Yavelow J, Finlay TH, Kennedy AR, Troll W: Bowman-Birk soybean protease inhibitor as an anticarcinogen. Cancer Res 43:2454–2459, 1983
Billings PC, Brandon DL, Habres JM: Internalization of the Bowman-Birk protease inhibitor by intestinal epithelial cells. Eur J Cancer 27:903–908, 1991
Cooper HS, Murthy SNS, Shah RS, Sedergran DJ: Clinicopathologic study of dextran sulfate sodium in experimental murine colitis. Lab Invest 69:238–249, 1993
Cooper HS, Murthy SNS: Displasia in dextran sulfate sodium (DSS) experimental murine colitis.Gastroenterology 106:A378, 1994
Dielman LA, Ridwan BU, Tennyson GS, Beagley KW, Bucy RP, Elson CO: Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 107:1643–1652, 1994
Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagake Y, Nakaya R: A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98:694–702, 1990
Zar JH: Biostatistical Analysis. Upper Saddle River, New Jersey, Prentice Hall, 1996
Rights and permissions
About this article
Cite this article
Ware, J.H., Wan, X.S., Newberne, P. et al. Bowman-Birk Inhibitor Concentrate Reduces Colon Inflammation in Mice with Dextran Sulfate Sodium-Induced Ulcerative Colitis. Dig Dis Sci 44, 986–990 (1999). https://doi.org/10.1023/A:1026616832119
Issue Date:
DOI: https://doi.org/10.1023/A:1026616832119